

Original article

Performance of lipid fingerprint-based MALDI-ToF for the diagnosis of mycobacterial infections

Ximena Gonzalo¹, Agnieszka Broda¹, Francis Drobniowski^{1, **}, Gerald Larrouy-Maumus^{2, *}¹ Department of Infectious Diseases, Faculty of Medicine, Imperial College London, London, W12 0NN, UK² MRC Centre for Molecular Bacteriology and Infection, Department of Life Sciences, Faculty of Natural Sciences, Imperial College London, London, SW7 2AZ, UK

ARTICLE INFO

Article history:

Received 24 June 2020

Received in revised form

21 August 2020

Accepted 21 August 2020

Available online 27 August 2020

Editor: F. Allerberger

Keywords:

Diagnostics

Evaluation

Lipids

MALDI

Mycobacteria

ABSTRACT

Objectives: Bacterial diagnosis of mycobacteria is often challenging because of the variability of the sensitivity and specificity of the assay used, and it can be expensive to perform accurately. Although matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS) has become the workhorse of clinical laboratories, the current MALDI methodology (which is based on cytosolic protein profiling) for mycobacteria is still challenging due to the number of steps involved (up to seven) and potential biosafety concerns. Knowing that mycobacteria produce surface-exposed species-specific lipids, we here hypothesized that the detection of those molecules could offer a rapid, reproducible and robust method for mycobacterial identification.

Methods: We evaluated the performance of an alternative methodology based on characterized species-specific lipid profiling of intact bacteria, without any sample preparation, by MALDI MS; it uses MALDI-time-of-flight (ToF) MS combined with a specific matrix (super-2,5-dihydroxybenzoic acid solubilized in an apolar solvent system) to analyse lipids of intact heat-inactivated mycobacteria. Cultured mycobacteria are heat-inactivated and loaded directly onto the MALDI target followed by addition of the matrix. Acquisition of the data is done in both positive and negative ion modes. Blinded studies were performed using 273 mycobacterial strains comprising both the *Mycobacterium tuberculosis* (Mtb) complex and non-tuberculous mycobacteria (NTMs) subcultured in Middlebrook 7H9 media supplemented with 10% OADC (oleic acid/dextrose/catalase) growth supplement and incubated for up to 2 weeks at 37°C.

Results: The method we have developed is fast (<10 mins) and highly sensitive (<1000 bacteria required); 96.7% of the Mtb complex strains (204/211) were correctly assigned as MTB complex and 91.7% (22/24) NTM species were correctly assigned based only on intact bacteria species-specific lipid profiling by MALDI-ToF MS.

Conclusions: Intact bacterial lipid profiling provides a biosafe and unique route for rapid and accurate mycobacterial identification. **Ximena Gonzalo, Clin Microbiol Infect 2021;27:912.e1–912.e5**

© 2020 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Introduction

Tuberculosis is one of the biggest infectious disease killers in the world, remaining in the top ten causes of mortality worldwide [1]. Control of the disease is hampered by multiple factors, including the difficulties in getting a timely and accurate diagnosis, a key pillar in the WHO End TB Strategy [2]. In the last few decades, matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF) has been implemented in the general bacteriology laboratory, revolutionizing bacterial identification; it has also been useful in

* Corresponding author. Gerald Larrouy-Maumus, MRC Centre for Molecular Bacteriology and Infection, Department of Life Sciences, Faculty of Natural Sciences, Imperial College London, London, SW7 2AZ, UK.

** Corresponding author. Francis Drobniowski, Department of Infectious Diseases, Faculty of Medicine, Imperial College London, London, UK.

E-mail addresses: f.drobniowski@imperial.ac.uk (F. Drobniowski), g.larrouy-maumus@imperial.ac.uk (G. Larrouy-Maumus).

the identification of mycobacteria and antibiotic resistance [3,4]. However, its broad application for mycobacteria has been challenging due to the fact that sample preparation and handling should happen in biosafety level 3 facilities, and that the mycobacterial wall needs special treatment to allow the molecules of interest to be released for MALDI-ToF proteomic analysis. This is time-consuming and requires a careful extraction step [5]. A novel approach has been described recently which aims to identify *Mycobacterium tuberculosis* based on MALDI-ToF mass spectrometry (MS) analysis of lipids from intact bacteria that would overcome, at least partially, the issues stated above [6].

The mycobacterial wall is composed of 60% lipids such as C-mycoside glycopeptidolipid, phenol glycosides, trehalose-containing lipopolysaccharides, sulpholipids, lipoarabinomannan, and mycolic acids [7]. The plasma membrane, the innermost layer, consists of a lipid bilayer interacting with proteins, peptidoglycan, arabinogalactan and polysaccharides esterified with mycolic acids. The free lipids associated with the outer membrane are very complex and structurally diverse [8]. Some lipids—such as sulphoglycolipids (SL-I) and the polyacyltrehaloses (PATs)—are specific for the *M. tuberculosis* complex; other lipids, such as C-mycoside glycopeptidolipids (GPLs), are found only in non-tuberculous mycobacteria (NTM) (e.g. *M. avium*) [9,10].

A simple procedure which can identify Mtb and drug resistance quickly and cheaply using standard commercially available MALDI-ToF instruments in clinical microbiology laboratories would be a significant asset in relation to turn-around times, enabling more timely clinical decision making.

The aim of this study was to establish a methodology to differentiate *M. tuberculosis* isolates from the NTM group and within NTM species based on species-specific lipid profiling using lipid fingerprints in MALDI-ToF MS on intact bacteria.

Material and methods

Clinical *Mycobacterium tuberculosis* isolates

A total of 273 mycobacterial isolates archived at Imperial College, London, UK were cultured from frozen aliquots into Middlebrook 7H9 broth supplemented with OACD (oleic acid/dextrose/catalase) without glycerol (Sigma-Aldrich Company Ltd, Gillingham, Dorset, UK) and incubated for 4–6 weeks at 37°C. The isolates comprised 244 Mtb isolates of different lineages (Beijing, Ural, Ghana-like1, Ghana-like2, X-like, EAJ, Haarlem, LAM) and 29 NTM isolates including 17 species (*M. abscessus*, *M. avium* (x2), *M. bohemicum* (x2), *M. celatum* (x2), *M. fortuitum* (x2), *M. interjectum*, *M. intracellulare*, *M. kansasii*, *M. marinum* (x2), *M. mucogenicum* (x2), *M. nonchromogenicum* (x2), *M. peregrinum* (x2), *M. phlei* (x2), *M. shimoidei* (x2), *M. simiae* (x2), *M. smegmatis* (x2), and *M. xenopi*). Mtb cultures were originally isolated from sputa of patients with pulmonary *M. tuberculosis* infections and whole-genome sequencing (WGS) was obtained for all of them. A collection of NTM reference strains was obtained from the European Centre for Disease Prevention and Control (ECDC) Reference Laboratory Network.

Sample preparation

Once optimal growth of the bacteria was obtained, 100 µL of bacterial suspension were placed into 1.5 mL Eppendorf tubes and heat-killed at 95°C for 30 min before leaving the BSL3 containment area. The heat-killed Mtb and NTM pellets were washed four times with 200 µL of double-distilled water. Then, a 0.4 µL aliquot of the resuspended pellet was pipetted onto the MALDI matrix plate and mixed with 0.8 µL of the MALDI matrix. The matrix used consisted

of a 9:1 mixture of 2,5-dihydroxybenzoic acid and 2-hydroxy-5-methoxybenzoic acid (super-DHB, Sigma-Aldrich) at a concentration of 10 mg/mL in chloroform:methanol 9:1. (Supplementary Material Fig. S1). All solvent manipulations and handling were carried out under a fume hood.

Mass spectrometry analysis

An Applied Biosystems 4800 MALDI TOF/TOF™ Analyzer (Applied Biosystems/MDS SCIEX MDS Sciex, Concord, Ontario, Canada) was used. Samples were analysed in the positive and negative ion mode operating at 20 kV and were set to acquire mass spectral peaks with mass/charge ratio (*m/z*) from 400 to 4000 mass units. Mass spectrometry data were analysed using Data Explorer® Software version 4.9 from Applied Biosystems and assignment of Mtb/NTM was performed blinded, after visual interpretation of spectra following criteria previously published [10]. Two people performed the visual assessment independently.

Statistical analysis

Sensitivity, specificity and 95% confidence intervals were calculated as described in the literature [11–14].

Results

The study examined the lipidomic profile of the TB isolates by MALDI-ToF mass spectrometry. In total, 273 isolates were tested (244 Mtb isolates and 29 NTM isolates). The mass spectra were acquired in both positive and negative mode.

Analysis of the mass spectra was conducted blindly. A good mycobacterial mass spectral signal (resolution >300 and signal-to-noise >5) in negative mode was generated for 235 out of 273 isolates; 38 isolates (14%) could not be assigned to either the Mtb or the NTM group, and nine isolates (3%) were misidentified. Good signals (resolution >300 and signal-to-noise >5) for most of the NTMs were generated in positive and negative ion modes. The 226 isolates of 235 which were correctly assigned (Table 1) were based on the negative mode signature for Mtb and the positive mode signatures for NTMs. All data were compared to molecular identification and reference strains inventory designation from the ECDC European Reference Laboratory Network. Identification of Mtb was achieved by the presence of SL-I, which is a negatively charged lipid uniquely found in Mtb [15,16]. Within the NTM group (29 clinical isolates), identification was performed in the positive ion mode by the ionization of species-specific lipid fingerprint—such as glycopeptidolipids, C-mycosides, polar glycopeptidolipids, glycerol monomycolate and phenolic glycolipids [17–28]—associated to each of the species exhibiting distinct and unique signatures or ‘chemical barcoding’, allowing clear discrimination of the NTM clinical isolates from each other presented in this study (Supplementary Material Fig. S2).

Nine isolates (3%) gave discrepant results compared to molecular DNA-derived identification and/or other biochemical analysis underpinning the designation by the ECDC European Reference Laboratory network; 7/211 Mtb strains were wrongly identified as NTMs and 2/24 NTMs (*M. nonchromogenicum* and *M. smegmatis*) were assigned as Mtb by MALDI-ToF. The 38/273 uninterpretable isolates (14%) were tested twice from the same heat-killed washed pellets. The results remained the same, i.e. uninterpretable. Of those 38 isolates, 33 were Mtb and five NTM isolates. Regarding the five NTM isolates—*M. abscessus*, *M. mucogenicum*, *M. phlei*, *M. shimoidei* (x2)—the quality of the spectra was poor associated with a low signal-to-noise (<5) precluding a convincing assignment of the data generated. For the 33 Mtb isolates (distributed across

Table 1
Sensitivity and specificity of the lipid fingerprint-based matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF) method

Mycobacterial identification (n = 235)		WGS		Sensitivity (%)	Specificity (%)
		Positive	Negative		
MALDI-ToF	Positive	204	2	96.7	91.7
	Negative	7	22		

WGS, whole-genome sequencing.

Beijing, Ghana-like 1, Latin American Mediterranean and clade A groups), as our method relies mainly on the presence of SL-I, failure to assign these as Mtb strains could be explained by the low abundance of SL-I in those strains, i.e. below the limit of detection. It has been reported in the literature that some Mtb strains within the same Mtb lineages can have low or no detectable SL-I [29]. Therefore, variations in the content of sulphatides can explain the un-interpretability of the 33 Mtb isolates, and further work needs to be carried out in order to confirm or refute this hypothesis.

The sensitivity and specificity of the MALDI-ToF (excluding un-interpretable results) was 96.7% (204/211; 95%CI 93.3–98.5%) and 91.7% (22/24; 95%CI 73.0–98.9%) respectively (Table 1).

Discussion

Current proteomic approaches require several extraction steps and incubation times for disruption of the bacteria in order to gain access to intracellular proteins [30–34]. By contrast, the lipidomics approach allows the identification of surface-exposed species-specific lipids, and is performed in a two-step process, making workflow in the laboratory very straightforward (Supplementary Material Table S1).

MALDI-ToF MS using an intact bacterial lipidomics approach generated high-quality interpretable spectra for 86% of the samples tested (235/273), with a sensitivity (96.7%; 204/211)—very similar to that of the quickest proteomics approach on MALDI-ToF that

identified 91.7% at species/complex level and an additional 4.4% to genus level [35]—but with the advantage of a single processing step after heat inactivation (Supplementary Material Table S1). Furthermore the samples were heat-treated pre-analysis, rendering the Mtb cultures safe for analysis.

Phosphatidylinositol mannosides (PIMs), sulpholipids (SL-I) and NTM species-specific lipids were easily recognized visually using this method, allowing for genus [36] and Mtb complex identification respectively. When the spectra were poor quality, non-genus-level identification was still possible. Failure to produce a good quality signal might be due to poor sample quality. It was not related specifically to NTM or Mtb cultures. The sensitivity and specificity for isolates for which a spectrum was identifiable was 96.7% (204/211) and 91.7% (22/24), respectively. Such percentages are higher than those found when using a protein-based approach [32,37–40], suggesting that the lipid-based approach is a very promising tool for the identification of mycobacteria by MALDI-ToF.

The MALDI-ToF instrument used in this study offered the possibility of obtaining spectra in both positive and negative ion modes. Negative ion mode showed better definition for Mtb while positive ion mode was better for NTM isolates. The MALDI-ToF system is widely available, and has a low consumable costs [41]. A flowchart exploring how this method could be implemented in the laboratory can be found in Fig. 1.

Newer systems such as the Bruker Sirius will become the next generation of clinical microbiology systems operating in positive




Fig. 1. Proposed flowchart. With modern clinical matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF) systems delivering positive and negative ion modes (e.g. Bruker Biotyper Sirius), an inexpensive, rapid, direct pathway from mycobacterial culture to identification is possible (red arrows). For systems with positive ion mode only, an initial rapid TB antigen test can identify *Mycobacterium tuberculosis* complex (MTB) cultures with information on non-tuberculous mycobacteria (NTMs) by MALDI-ToF acting as additional confirmation.

and negative ion modes. Currently, most clinical laboratories have systems which operate in positive ion mode only. Where this is the case, a combination of inexpensive rapid antigen testing (MBT64) combined with lipidomic MALDI-ToF analysis would provide definitive TB identification (TB or not TB, and likely NTM species) rapidly and cheaply in all clinical laboratories and provide species-level identification for NTMs which can have immediate management implications in certain populations (cystic fibrosis, non-cystic fibrosis bronchiectasis, cardiothoracic surgery, immunosuppressed individuals) [42–46].

This study has some limitations. *Mtb* complex subspecies, such as *M. africanum*, and the animal-adapted *M. caprae*, *M. bovis*, *M. microti*, *M. pinnipedii*, and '*M. canettii*', as well as NTMs belonging to the *M. abscessus* complex for example, were not included. We plan further studies to confirm that such a species-specific lipid-based approach allows the identification and discrimination of other mycobacteria within the *Mtb* complex, distinguishing *M. chimera* from *M. intracellulare*, and ultimately providing the drug susceptibility profile of clinical isolates. For this last, a promising avenue would still be the analysis of lipids, as Lahiri and colleagues reported that rifampicin-resistant mutations are associated with altered concentrations of mycobacterial lipids such as SL-I [47]. Future work will ascertain whether this study can be reproduced using instruments available in routine microbiology laboratories with the same matrix (super-DHB) but a less toxic solvent such as ethanol instead of the chloroform used here. This study was conducted with a MALDI mass spectrometer operating in both positive and negative ion mode, which not all clinical microbiology laboratories have access to at the moment. However, as the next generation of clinical microbiology MALDI-ToF identification systems will likely utilize both positive and negative ion modes to increase diagnostic potential (e.g. Bruker Biotyper Sirius), mycobacteria can be identified with confidence as MTB complex or NTM rapidly, safely and inexpensively. The newer MALDI-ToF systems will increase the reliability of NTM species and subspecies identification. As part of this process, automated software based on the lipid fingerprint of each mycobacterium should be implemented for rapid identification and to simplify data analysis. Indeed, we are a step closer to the possibility of detailed identification to species level and detection of significant antibiotic resistance from a single spectrum in any clinical microbiology laboratory.

Author contributions

XG, AB, FD and GL-M designed and performed the experiments. XG, AB, FD and GL-M analysed the data. All co-authors contributed to writing the paper.

Transparency declaration

FD and GL-M are co-inventors of the rapid detection of mycobacteria based on species-specific lipids, for which a patent has been filed by Imperial Technology Transfer. The remaining authors have no conflicts of interest to declare. This study was supported by the MRC Confidence in Concept Fund and the ISSF Wellcome Trust Grant 105603/Z/14/Z (to GL-M and FD).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.cmi.2020.08.027>.

References

- [1] World Health Organization. The top 10 causes of death 2018. 2020. WHO Fact Sheets]. Available from: <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>.
- [2] World Health Organization. The End TB Strategy—global strategy and targets for tuberculosis prevention, care and control after 2015. 2018.
- [3] Akyar I, Çavuşoğlu C, Ayaş M, Sürücüoğlu S, İlki A, Kaya DE, et al. Evaluation of the performance of MALDI-TOF MS and DNA sequence analysis in the identification of mycobacteria species. *Turk J Med Sci* 2018;48:1351–7.
- [4] Vrioni G, Tsiamis C, Oikonomidis G, Theodoridou K, Kapsimali V, Tsakris A. MALDI-TOF mass spectrometry technology for detecting biomarkers of antimicrobial resistance: current achievements and future perspectives. *Ann Transl Med* 2018;6:240.
- [5] Alcaide F, Amlerová J, Bou G, Ceyssens PJ, Coll P, Corcoran D, et al. How to identify non-tuberculous *Mycobacterium* species using MALDI-TOF mass spectrometry. *Clin Microbiol Infect* 2018;24:599–603.
- [6] Larrouy-Maumus G, Puzo G. Mycobacterial envelope lipids fingerprint from direct MALDI-TOF MS analysis of intact bacilli. *Tuberculosis* 2015;95:75–85.
- [7] Wang JL, Patten SB, Currie S, Sareen J, Schmitz N. Predictors of 1-year outcomes of major depressive disorder among individuals with a lifetime diagnosis: a population-based study. *Psychol Med* 2011;1–10.
- [8] Yokoyama A, Kage H, Ohama Y, Sato T, Miyashita N, Noguchi S, et al. *Mycobacterium heckeshornense* lung infection diagnosed by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS). *J Infect Chemother* 2018;24:763–5.
- [9] Laval F, Lanéelle MA, Déon C, Monsarrat B, Daffé M. Accurate molecular mass determination of mycolic acids by MALDI-TOF mass spectrometry. *Anal Chem* 2001;73:4537–44.
- [10] Larrouy-Maumus G, Puzo G. Mycobacterial envelope lipids fingerprint from direct MALDI-TOF MS analysis of intact bacilli. *Tuberculosis* 2015;95:75–85.
- [11] Mercaldo ND, Lau KF, Zhou XH. Confidence intervals for predictive values with an emphasis to case–control studies. *Stat Med* 2007;26:2170–83.
- [12] Zhou XH, Qin G. Improved confidence intervals for the sensitivity at a fixed level of specificity of a continuous-scale diagnostic test. *Stat Med* 2005;24:465–77.
- [13] Griner PF, Mayewski RJ, Mushlin AI, Greenland P. Selection and interpretation of diagnostic tests and procedures. Principles and applications. *Ann Intern Med* 1981;94:557–92.
- [14] Qin G, Hsu YS, Zhou XH. New confidence intervals for the difference between two sensitivities at a fixed level of specificity. *Stat Med* 2006;25:3487–502.
- [15] Layre E, Paepe DC, Larrouy-Maumus G, Vaubourgeix J, Mundayoor S, Lindner B, et al. Deciphering sulfolipolipids of *Mycobacterium tuberculosis*. *J Lipid Res* 2011;52:1098–110.
- [16] Goren MB. Sulfolipid I of *Mycobacterium tuberculosis*, strain H37Rv. II. Structural studies. *Biochim Biophys Acta* 1970;210:127–38.
- [17] Brennan PJ, Goren MB. Structural studies on the type-specific antigens and lipids of the *Mycobacterium avium*, *Mycobacterium intracellulare*, *Mycobacterium scrofulaceum* serocomplex, *Mycobacterium intracellulare* serotype 9. *J Biol Chem* 1979;254:4205–11.
- [18] Aspinall GO, Khare NK, Sood RK, Chatterjee D, Rivoire B, Brennan PJ. Structure of the glycopeptidolipid antigen of serovar 20 of the *Mycobacterium avium* serocomplex, synthesis of allyl glycosides of the outer di- and tri-saccharide units of the antigens of serovars 14 and 20, and serology of the derived neoglycoproteins. *Carbohydr Res* 1991;216:357–73.
- [19] Aspinall GO, Gammon DW, Sood RK, Chatterjee D, Rivoire B, Brennan PJ. Structures of the glycopeptidolipid antigens of serovars 25 and 26 of the *Mycobacterium avium* serocomplex, synthesis of allyl glycosides of the outer disaccharide units and serology of the derived neoglycoproteins. *Carbohydr Res* 1992;237:57–77.
- [20] Torrelles JB, Ellis D, Osborne T, Hoefler A, Orme IM, Chatterjee D, et al. Characterization of virulence, colony morphotype and the glycopeptidolipid of *Mycobacterium avium* strain 104. *Tuberculosis* 2002;82:293–300.
- [21] Gautier N, Lopez Marin LM, Laneelle MA, Daffe M. Structure of mycoside F, a family of trehalose-containing glycolipids of *Mycobacterium fortuitum*. *FEMS Microbiol Lett* 1992;77:81–7.
- [22] Lopez Marin LM, Laneelle MA, Prome D, Daffe M, Laneelle G, Prome JC. Glycopeptidolipids from *Mycobacterium fortuitum*: a variant in the structure of C-mycoside. *Biochemistry* 1991;30:10536–42.
- [23] Lopez-Marin LM, Gautier N, Laneelle MA, Silve G, Daffe M. Structures of the glycopeptidolipid antigens of *Mycobacterium abscessus* and *Mycobacterium chelonae* and possible chemical basis of the serological cross-reactions in the *Mycobacterium fortuitum* complex. *Microbiology* 1994;140:1109–18.
- [24] Brennan PJ, Nikaido H. The envelope of mycobacteria. *Annu Rev Biochem* 1995;64:29–63.
- [25] Schorey JS, Sweet L. The mycobacterial glycopeptidolipids: structure, function, and their role in pathogenesis. *Glycobiology* 2008;18:832–41.
- [26] Riviere M, Puzo G. A new type of serine-containing glycopeptidolipid from *Mycobacterium xenopi*. *J Biol Chem* 1991;266:9057–63.
- [27] Fournie JJ, Riviere M, Papa F, Puzo G. Structural elucidation of the major phenolic glycolipid from *Mycobacterium kansasii*. II. Presence of a novel dideoxyhexose. *J Biol Chem* 1987;262:3180–4.

- [28] Fournie JJ, Riviere M, Puzo G. Structural elucidation of the major phenolic glycolipid from *Mycobacterium kansasii*. I. Evidence for tetrasaccharide structure of the oligosaccharide moiety. *J Biol Chem* 1987;262:3174–9.
- [29] Krishnan N, Malaga W, Constant P, Caws M, Tran TH, Salmons J, et al. *Mycobacterium tuberculosis* lineage influences innate immune response and virulence and is associated with distinct cell envelope lipid profiles. *PLoS One* 2011;6:e23870.
- [30] Murugaiyan J, Lewin A, Kamal E, Bakula Z, van Ingen J, Ullmann V, et al. MALDI spectra database for rapid discrimination and subtyping of *Mycobacterium kansasii*. *Front Microbiol* 2018;9:587.
- [31] Mediavilla-Gradolph MC, De Toro-Peinado I, Bermudez-Ruiz MP, Garcia-Martinez Mde L, Ortega-Torres M, Montiel Quezel-Guerraz N, et al. Use of MALDI-TOF MS for identification of nontuberculous *Mycobacterium* species isolated from clinical specimens. *Biomed Res Int* 2015;2015:854078.
- [32] Cao Y, Wang L, Ma P, Fan W, Gu B, Ju S. Accuracy of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of mycobacteria: a systematic review and meta-analysis. *Sci Rep* 2018;8:4131.
- [33] Shitikov E, Iliina E, Chernousova L, Borovskaya A, Rukin I, Afanas'ev M, et al. Mass spectrometry based methods for the discrimination and typing of mycobacteria. *Infect Genet Evol* 2012;12:838–45.
- [34] Rodriguez-Sanchez B, Ruiz-Serrano MJ, Ruiz A, Timke M, Kostrzewa M, Bouza E. Evaluation of MALDI Biotyper Mycobacteria Library v3.0 for identification of nontuberculous mycobacteria. *J Clin Microbiol* 2016;54:1144–7.
- [35] Rotcheewaphan S, Lemon JK, Desai UU, Henderson CM, Zelazny AM. Rapid one-step protein extraction method for the identification of mycobacteria using MALDI-TOF MS. *Diagn Microbiol Infect Dis* 2019;94:355–60.
- [36] Rahlwes KC, Puffal J, Morita YS. Purification and analysis of mycobacterial phosphatidylinositol mannosides, lipomannan, and lipoarabinomannan. In: Brockhausen I, editor. *Bacterial polysaccharides: methods and protocols*. New York, NY: Springer New York; 2019. p. 59–75.
- [37] Huang TS, Lee CC, Tu HZ, Lee SS. Rapid identification of mycobacteria from positive MGIT broths of primary cultures by MALDI-TOF mass spectrometry. *PLoS One* 2018;13:e0192291.
- [38] Alcaide F, Amlerova J, Bou G, Ceyssens PJ, Coll P, Corcoran D, et al. How to identify non-tuberculous *Mycobacterium* species using MALDI-TOF mass spectrometry. *Clin Microbiol Infect* 2018;24:599–603.
- [39] Quinlan P, Phelan E, Doyle M. Matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry (MS) for the identification of mycobacteria from MBBacT ALERT 3D liquid cultures and Lowenstein–Jensen (LJ) solid cultures. *J Clin Pathol* 2015;68:229–35.
- [40] Rodriguez-Temporal D, Perez-Risco D, Struzka EA, Mas M, Alcaide F. Evaluation of two protein extraction protocols based on freezing and mechanical disruption for identifying nontuberculous mycobacteria by matrix-assisted laser desorption ionization-time of flight mass spectrometry from liquid and solid cultures. *J Clin Microbiol* 2018;56:e01548.
- [41] El-Bouri K, Johnston S, Rees E, Thomas I, Bome-Mannathoko N, Jones C, et al. Comparison of bacterial identification by MALDI-TOF mass spectrometry and conventional diagnostic microbiology methods: agreement, speed and cost implications. *Br J Biomed Sci* 2012;69:47–55.
- [42] Furukawa BS, Flume PA. Nontuberculous mycobacteria in cystic fibrosis. *Semin Respir Crit Care Med* 2018;39:383–91.
- [43] McShane PJ, Naureckas ET, Tino G, Streck ME. Non-cystic fibrosis bronchiectasis. *Am J Respir Crit Care Med* 2013;188:647–56.
- [44] Johnson MM, Odell JA. Nontuberculous mycobacterial pulmonary infections. *J Thorac Dis* 2014;6:210–20.
- [45] Campins Marti M, Borrás Bermejo B, Armadans Gil L. Infections with *Mycobacterium chimaera* and open chest surgery. An unresolved problem. *Med Clin (Barc)* 2019;152:317–23.
- [46] Henkle E, Winthrop KL. Nontuberculous mycobacteria infections in immunosuppressed hosts. *Clin Chest Med* 2015;36:91–9.
- [47] Lahiri N, Shah RR, Layre E, Young D, Ford C, Murray MB, et al. Rifampin resistance mutations are associated with broad chemical remodeling of *Mycobacterium tuberculosis*. *J Biol Chem* 2016;291:14248–56.